首页> 外文期刊>Journal of clinical psychopharmacology >Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.
【24h】

Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.

机译:精神分裂症门诊病人的缓解和复发:精神分裂症门诊病人健康结果研究的三年结果。

获取原文
获取原文并翻译 | 示例
           

摘要

Remission and relapse are clinical outcomes of increasing interest in schizophrenia. We analyzed remission and relapse, and the sociodemographic and clinical factors associated with these outcomes, in the usual care of schizophrenia using the 3-year, follow-up data from a large cohort of outpatients with schizophrenia taking part in the prospective, observational, European Schizophrenia Outpatient Health Outcomes study. Of the 6516 patients analyzed for remission, 4206 (64.6%) achieved remission during the 3-year, follow-up period. Logistic regression analysis revealed that being female, having a good level of social functioning at study entry, and a shorter duration of illness were factors significantly associated with achieving remission. Treatment with olanzapine was also associated with a higher frequency of remission compared with other antipsychotic agents. A Kaplan-Meier survival curve estimated that relapse occurred in approximately 25% of the patients who achieved remission, with the risk of relapse remaining constant during the follow-up period. Shorter duration of illness, having hostile behaviors, and substance abuse were factors associated with a higher risk of relapse, whereas good level of social functioning and the use of olanzapine and clozapine were associated with a lower risk of relapse. In conclusion, the 3-year results of the Schizophrenia Outpatient Health Outcomes study indicate that the likelihood of remission decreases over the longitudinal course of schizophrenia, but risk of relapse is maintained even after 3 years of achieving remission severity levels. Results suggest that treatment with olanzapine is associated with a better chance of achieving remission than other antipsychotics. Moreover, the use of olanzapine and clozapine is associated with a lower risk of relapse compared with risperidone, quetiapine, and typical antipsychotics. The results should be interpreted conservatively because of the observational, nonrandomized study design.
机译:缓解和复发是对精神分裂症越来越感兴趣的临床结果。我们使用来自前瞻性,观察性,欧洲人的大量精神分裂症门诊患者的3年随访数据,分析了精神分裂症的常规护理中的缓解和复发以及与这些结果相关的社会人口统计学和临床​​因素精神分裂症门诊健康结果研究。在接受分析的6516例患者中,有3例随访了4206例(64.6%)缓解。 Logistic回归分析表明,女性,在研究进入时具有良好的社会功能以及较短的疾病持续时间是与实现缓解显着相关的因素。与其他抗精神病药相比,奥氮平治疗还具有较高的缓解频率。 Kaplan-Meier生存曲线估计,复发的患者中约有25%发生了复发,并且在随访期间复发的风险保持恒定。疾病持续时间较短,有敌对行为和药物滥用是复发风险较高的因素,而良好的社会功能以及使用奥氮平和氯氮平的复发风险较低。总之,精神分裂症门诊健康结果研究的3年结果表明,在精神分裂症的纵向过程中,缓解的可能性降低,但是即使达到缓解严重程度水平的3年,复发的风险仍然存在。结果表明,与其他抗精神病药物相比,奥氮平治疗与缓解相关的机会更大。此外,与利培酮,喹硫平和典型的抗精神病药相比,使用奥氮平和氯氮平的复发风险较低。由于采用观察性,非随机的研究设计,因此应保守地解释结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号